Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
DNA topoisomerase I/II inhibitor
Intoplicine is a DNA topoisomerase I and II inhibitor. -
telomerase inhibitor
TMPyP4 tosylate (TMP 1363) is a telomerase inhibitor with antitumor effects in osteosarcoma cell lines. -
PARP1/2 inhibitor
Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.- Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
-
PARP-2 inhibitor
PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC50 of 11.5 nM. -
pan HDAC inhibitor
Tefinostat (CHR-2845) is a monocyte/macrophage-targeted pan HDAC inhibitor, cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Anti-monocytoid lineage leukaemias activity. -
HDAC inhibitor
Oxamflatin (Metacept-3) is a potent HDAC inhibitor with an IC50 of 15.7 nM. -
PARG inhibitor
PDD 00017273 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with an IC50 of 26 nM, and a KD of 1.45 nM. -
BRCA1 inhibitor
BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively. -
PPI inhibitor
BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions. -
eIF4G1 inhibitor
SBI-0640756 (SBI-756) is a water soluble inhibitor of eIF4G1 and disrupts the eIF4F complex. -
PNP inhibitor
Forodesine(BCX-1777 freebase; Immucillin-H) is an orally bioavailable PNP inhibitor with picomolar potency; induces apoptosis, mainly in T cells. -
PNP inhibitor
Forodesine hydrochloride (BCX-1777) is a highly potent and specific purine nucleoside phosphorylase (PNP) inhibitor. -
RdRp inhibitor
Galidesivir hydrochloride (BCX 4430 hydrochloride) is a viral RNA-dependent RNA polymerase (RdRp) inhibitor; demonstrated broad-spectrum activity in multiple viruses and a favorable preliminary preclinical safety profile. -
HDAC inhibitor
CG-200745 is a potent HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. -
HDAC1 inhibitor
Domatinostat tosylate (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). -
DNA synthesis inhibitor
Thiarabine (OSI-7836) shows potent anti-tumor activity and inhibition of DNA synthesis. -
topoisomerase II inhibitor
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. -
HDAC inhibitor
Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. -
topoisomerase I inhibitor
Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity. -
Topoisomerase I inhibitor
Edotecarin is a potent inhibitor of topoisomerase I that can induces single-strand DNA cleavage, with IC50 of 50 nM. -
PARP inhibitor
Veliparib dihydrochloride is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively. -
DNA-PK inhibitor
(Rac)-Nedisertib ((Rac)-M3814) is a racemate of Nedisertib, a potent DNA-PK inhibitor, with an IC50 of <3 nM. -
gyrase B inhibitor
VXc-486 is a gyrase B inhibitor, with bactericidal activity.
